OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)
South Korea · Delayed Price · Currency is KRW 5,720.00
-70.00 (-1.21%)
At close: Sep 4, 2026
OPTUS Pharmaceutical Revenue
OPTUS Pharmaceutical had revenue of 24.64B KRW in the quarter ending June 30, 2026, with 13.07% growth. This brings the company's revenue in the last twelve months to 94.47B, up 14.08% year-over-year. In the year 2025, OPTUS Pharmaceutical had annual revenue of 87.16B with 6.42% growth.
Revenue (ttm)
94.47B
Revenue Growth
+14.08%
P/S Ratio
1.07
Revenue / Employee
n/a
Employees
n/a
Market Cap
100.94B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 87.16B | 5.26B | 6.42% |
| Dec 31, 2024 | 81.90B | 9.48B | 13.09% |
| Dec 31, 2023 | 72.43B | 13.77B | 23.47% |
| Dec 31, 2022 | 58.66B | 1.34B | 2.34% |
| Dec 31, 2021 | 57.32B | -3.51B | -5.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 345.08B |
| H.PIO | 269.63B |
| DongKoo Bio & Pharma | 241.43B |
| HYUNDAI BIOLAND | 140.70B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 111.72B |
| Hwail Pharmaceutical | 107.87B |
| KOREA PHARMA | 93.94B |
| Sam-A Pharm. | 72.28B |